Name | Number of supported studies | Average coverage | |
---|---|---|---|
naive B cell | 6 studies | 19% ± 2% | |
B cell | 3 studies | 19% ± 3% |
Insufficient scRNA-seq data for expression of NUAK2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 2903.19 | 652 / 653 | 95% | 23.58 | 573 / 605 |
lung | 97% | 1618.43 | 558 / 578 | 95% | 24.51 | 1102 / 1155 |
kidney | 100% | 3057.39 | 89 / 89 | 90% | 20.73 | 808 / 901 |
pancreas | 92% | 1066.09 | 303 / 328 | 83% | 10.05 | 147 / 178 |
intestine | 52% | 923.95 | 498 / 966 | 98% | 32.36 | 516 / 527 |
skin | 98% | 2568.32 | 1766 / 1809 | 41% | 5.06 | 194 / 472 |
esophagus | 40% | 2858.96 | 577 / 1445 | 98% | 38.99 | 179 / 183 |
stomach | 23% | 106.60 | 83 / 359 | 96% | 28.49 | 275 / 286 |
ovary | 18% | 85.15 | 33 / 180 | 100% | 86.03 | 429 / 430 |
liver | 53% | 339.74 | 120 / 226 | 64% | 15.12 | 261 / 406 |
prostate | 49% | 234.32 | 119 / 245 | 68% | 7.33 | 342 / 502 |
adrenal gland | 76% | 564.83 | 195 / 258 | 30% | 2.70 | 68 / 230 |
spleen | 100% | 2151.55 | 241 / 241 | 0% | 0 | 0 / 0 |
uterus | 12% | 237.85 | 20 / 170 | 87% | 26.67 | 400 / 459 |
tonsil | 0% | 0 | 0 / 0 | 98% | 34.22 | 44 / 45 |
lymph node | 0% | 0 | 0 / 0 | 97% | 27.39 | 28 / 29 |
breast | 8% | 46.17 | 39 / 459 | 86% | 12.49 | 967 / 1118 |
peripheral blood | 80% | 3448.77 | 747 / 929 | 0% | 0 | 0 / 0 |
bladder | 10% | 37.71 | 2 / 21 | 67% | 16.93 | 336 / 504 |
brain | 21% | 188.33 | 545 / 2642 | 31% | 3.56 | 222 / 705 |
adipose | 25% | 150.46 | 295 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 5% | 0.34 | 4 / 80 |
heart | 5% | 22.50 | 41 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 4% | 19.60 | 49 / 1335 | 0% | 0 | 0 / 0 |
muscle | 1% | 3.43 | 6 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006915 | Biological process | apoptotic process |
GO_0042149 | Biological process | cellular response to glucose starvation |
GO_0030036 | Biological process | actin cytoskeleton organization |
GO_0006468 | Biological process | protein phosphorylation |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0034504 | Biological process | protein localization to nucleus |
GO_0035330 | Biological process | regulation of hippo signaling |
GO_0005524 | Molecular function | ATP binding |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0005515 | Molecular function | protein binding |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0000287 | Molecular function | magnesium ion binding |
Gene name | NUAK2 |
Protein name | NUAK family SNF1-like kinase 2 (EC 2.7.11.1) (Omphalocele kinase 2) (SNF1/AMP kinase-related kinase) (SNARK) |
Synonyms | SNARK OMPHK2 |
Description | FUNCTION: Stress-activated kinase involved in tolerance to glucose starvation. Induces cell-cell detachment by increasing F-actin conversion to G-actin. Expression is induced by CD95 or TNF-alpha, via NF-kappa-B. Protects cells from CD95-mediated apoptosis and is required for the increased motility and invasiveness of CD95-activated tumor cells. Phosphorylates LATS1 and LATS2. Plays a key role in neural tube closure during embryonic development through LATS2 phosphorylation and regulation of the nuclear localization of YAP1 a critical downstream regulatory target in the Hippo signaling pathway . . |
Accessions | ENST00000367157.6 Q9H093 |